Doxa AB
STO:DOXA
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
1.01
3.5
|
| Price Target |
|
We'll email you a reminder when the closing price reaches SEK.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Doxa AB
Cash & Cash Equivalents
Doxa AB
Cash & Cash Equivalents Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Cash & Cash Equivalents | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
D
|
Doxa AB
STO:DOXA
|
Cash & Cash Equivalents
kr11.8m
|
CAGR 3-Years
121%
|
CAGR 5-Years
3%
|
CAGR 10-Years
10%
|
|
|
O
|
OssDsign AB
STO:OSSD
|
Cash & Cash Equivalents
kr165.9m
|
CAGR 3-Years
50%
|
CAGR 5-Years
64%
|
CAGR 10-Years
N/A
|
|
|
Xvivo Perfusion AB
STO:XVIVO
|
Cash & Cash Equivalents
kr450m
|
CAGR 3-Years
17%
|
CAGR 5-Years
18%
|
CAGR 10-Years
23%
|
|
|
Bactiguard Holding AB
STO:BACTI B
|
Cash & Cash Equivalents
kr123.2m
|
CAGR 3-Years
132%
|
CAGR 5-Years
131%
|
CAGR 10-Years
N/A
|
|
|
V
|
Vimian Group AB
STO:VIMIAN
|
Cash & Cash Equivalents
€39.2m
|
CAGR 3-Years
-23%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
S
|
S2Medical AB (publ)
STO:S2M
|
Cash & Cash Equivalents
kr1.4m
|
CAGR 3-Years
-48%
|
CAGR 5-Years
-45%
|
CAGR 10-Years
N/A
|
|
Doxa AB
Glance View
Doxa AB engages in the development, manufacture, and commercialization of bioceramic dental products. The company is headquartered in Uppsala, Uppsala. The company went IPO on 2014-04-07. The firm develops, manufactures and commercializes products based upon its technology platform of calcium aluminate hydrate and bioactive ceramics. Activities are divided into the therapy areas of orthopedics and odontology. Research areas within orthopedics are methods for treating fractures resulting from osteoporosis, reconstructive orthopedics and coating of implants. Research areas within odontology are tooth restoration and implant fixation.
See Also
What is Doxa AB's Cash & Cash Equivalents?
Cash & Cash Equivalents
11.8m
SEK
Based on the financial report for Jun 30, 2024, Doxa AB's Cash & Cash Equivalents amounts to 11.8m SEK.
What is Doxa AB's Cash & Cash Equivalents growth rate?
Cash & Cash Equivalents CAGR 10Y
10%
Over the last year, the Cash & Cash Equivalents growth was -92%. The average annual Cash & Cash Equivalents growth rates for Doxa AB have been 121% over the past three years , 3% over the past five years , and 10% over the past ten years .
You don't have any saved screeners yet
